{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=82", "query": { "intervention": "Injectable saline", "page": 82 }, "page_size": 10 }, "pagination": { "page": 82, "page_size": 10, "total_count": 2103, "total_pages": 211, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=83&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=81&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T22:37:30.519Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02212457", "title": "Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infections, Meningococcal" ], "interventions": [ { "name": "Bexsero", "type": "BIOLOGICAL" }, { "name": "Saline Placebo", "type": "OTHER" }, { "name": "Havrix", "type": "BIOLOGICAL" }, { "name": "MenABCWY", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "10 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "10 Years to 18 Years" }, "enrollment_count": 1063, "start_date": "2014-08-21", "completion_date": "2016-03-03", "has_results": true, "last_update_posted_date": "2019-06-27", "last_synced_at": "2026-11-07T22:37:30.519Z", "location_count": 13, "location_summary": "Jonesboro, Arkansas • Hialeah, Florida • Melbourne, Florida + 10 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Augusta", "state": "Kansas" }, { "city": "Niles", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02212457" }, { "nct_id": "NCT03933865", "title": "Acute Pain Management in Patients on Opioid Replacement Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Opioid-use Disorder", "Pain, Acute" ], "interventions": [ { "name": "HYDROmorphone Injectable Solution", "type": "DRUG" }, { "name": "Ketamine", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 1, "start_date": "2018-10-31", "completion_date": "2022-02-24", "has_results": false, "last_update_posted_date": "2022-10-10", "last_synced_at": "2026-11-07T22:37:30.519Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03933865" }, { "nct_id": "NCT06045936", "title": "A Study of Contralateral Limb Block", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Limb Pain, Phantom" ], "interventions": [ { "name": "Lidocaine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-06-18", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-11-07T22:37:30.519Z", "location_count": 1, "location_summary": "Mankato, Minnesota", "locations": [ { "city": "Mankato", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06045936" }, { "nct_id": "NCT00725881", "title": "Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Intermittent Claudication" ], "interventions": [ { "name": "Trans sodium crocetinate (TSC)", "type": "DRUG" }, { "name": "0.9% normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Diffusion Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 48, "start_date": "2008-08", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2011-07-29", "last_synced_at": "2026-11-07T22:37:30.519Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Santa Rosa, California • Stanford, California + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Pensacola", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00725881" }, { "nct_id": "NCT06062602", "title": "PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "TAK-676", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "TAK-676 + Carboplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Carboplatin + Paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "Carboplatin + 5-FU", "type": "COMBINATION_PRODUCT" }, { "name": "TAK-676 + Carboplatin + 5-FU", "type": "COMBINATION_PRODUCT" }, { "name": "TAK-676 + Carboplatin + Paclitaxel", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Presage Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-07-26", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-11-07T22:37:30.519Z", "location_count": 4, "location_summary": "Shreveport, Louisiana • The Bronx, New York • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Shreveport", "state": "Louisiana" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06062602" }, { "nct_id": "NCT02326272", "title": "A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis", "Plaque Psoriasis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 227, "start_date": "2014-12-15", "completion_date": "2018-09-12", "has_results": true, "last_update_posted_date": "2019-10-03", "last_synced_at": "2026-11-07T22:37:30.519Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Ormond Beach", "state": "Florida" }, { "city": "Portsmouth", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02326272" }, { "nct_id": "NCT01662895", "title": "High-Dose Deferoxamine in Intracerebral Hemorrhage", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intracerebral Hemorrhage" ], "interventions": [ { "name": "Deferoxamine", "type": "DRUG" }, { "name": "Normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 42, "start_date": "2013-03-18", "completion_date": "2018-05-10", "has_results": true, "last_update_posted_date": "2019-06-12", "last_synced_at": "2026-11-07T22:37:30.519Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01662895" }, { "nct_id": "NCT03927222", "title": "Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Tetanus-Diphtheria Toxoid (Td)", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "111-Indium-labeling of Cells for in vivo Trafficking Studies", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2019-09-30", "completion_date": "2023-02-10", "has_results": true, "last_update_posted_date": "2024-04-08", "last_synced_at": "2026-11-07T22:37:30.519Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03927222" }, { "nct_id": "NCT04917861", "title": "A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Zika Virus" ], "interventions": [ { "name": "mRNA-1893", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 808, "start_date": "2021-06-07", "completion_date": "2024-07-26", "has_results": true, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-11-07T22:37:30.519Z", "location_count": 3, "location_summary": "Sioux City, Iowa • Lenexa, Kansas • Fort Worth, Texas", "locations": [ { "city": "Sioux City", "state": "Iowa" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04917861" }, { "nct_id": "NCT01265745", "title": "Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anthrax" ], "interventions": [ { "name": "Normal Saline for Injection", "type": "DRUG" }, { "name": "MDX1303", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "PharmAthene, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 28, "start_date": "2010-12", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2013-12-09", "last_synced_at": "2026-11-07T22:37:30.519Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01265745" } ] }